Swipe om te navigeren naar een ander artikel
To explore whether determinants of global quality of life (QOL) change before and after major cancer surgery.
Consecutive patients (n = 145) undergoing surgery for upper gastrointestinal cancer were prospectively studied and asked to complete the EORTC QLQ-C30 before and after 6 months. Excluded were patients found to be inoperable (n = 12) and those with missing second questionnaires (because of death n = 20, poor health (n = 10), administrative failure (n = 7) or patient refusal (n = 4)). Multivariable linear regression models investigated associations between global QOL and other scales and items of QOL adjusting for clinical variables.
Some 87 patients completed both questionnaires. Before surgery the main predictors of global QOL were physical and emotional function, with adjusted increases in global QOL of 0.55 (95% CI 0.26–0.84; P < 0.001) and 0.30 (95% CI 0.14–0.45; P < 0.001) per unit increase of physical and emotional function, respectively. Six months after surgery, however, fatigue and dyspnea most strongly predicted global QOL, with adjusted differences in global QOL of −0.24 (95% CI −0.44 to −0.04; P = 0.02) per unit increase of fatigue and −6.28 (95% CI −12.64 to 0.07; P = 0.05) for those experiencing any symptoms of dyspnea.
Further work is needed to test these findings, but the results suggest that the global QOL scale in the QLQ-C30 is difficult to interpret and it should be considered within the context of other clinical and patient reported outcomes.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Food and Drug Administration. Patient-reported outcome measures: Use in medical product development to support labeling claims. DRAFT GUIDANCE. http://www.fda.gov/cder/guidance/5460dft.pdf. Accessed July 12, 2008.
Efficace, F., Kemmler, G., Vignetti, M., Mandelli, F., Molica, S., & Holzner, B. (2008). Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials—a systematic review to evaluate the added value in supporting clinical decision making. European Journal of Cancer,44, 1497–1506. PubMedCrossRef
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute,85, 365–376. PubMedCrossRef
Fayers, P., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) The EORTC QLQ-C30 scoring manual (3rd ed.). European Organisation for Research and Treatment of Cancer, Brussels.
Beijer, S., Kempen, G. I., Pijls-Johannesma, M. C., de Graeff, A., & Dagnelie, P. C. (2008). Determinants of overall quality of life in preterminal cancer patients. International Journal of Cancer,123, 232–235. CrossRef
Moinpour, C. M., Donaldson, G. W., & Redman, M. W. (2007). Do general dimensions of quality of life add clinical value to symptom data? Journal of the National Cancer Institute Monogr, 31–38.
- Determinants of global quality of life before and after major cancer surgery: an exploratory study
Jane M. Blazeby
- Springer Netherlands